Grape Seeds Extract Gel as an Adjunct for the Treatment of Chronic Periodontitis

NCT ID: NCT02767115

Last Updated: 2016-05-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to formulate a mucoadhesive gel of grapes seed extract (GSE) followed by short-term clinical study for the effectiveness of this gel onto the pocket depth (PD), plaque index (PI), gingival index (GI), and bleeding on probing (BOP) when applied in periodontal pockets as an adjunct treatment for chronic periodontitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Before commencing with the study, the trial proposal was registered in the research center and ethical clearance was taken from the ethical committee (FUGRP/2014/182)

Materials used in the study::

1. Pure Grape Seed Extract (GSE) supplied by pure bulk supplements (Bulksupplements, USA). It contains natural ingredient of more than 180 mg of proanthocyanidins for every 200 mg of serving size of the powder. GSE has been considered safe by the National Center for Complimentary and Integrative Health if used orally for up to 8 weeks of clinical trials
2. Carbapol "CB 934" (Loba Chemie Pvt. Ltd., Mumbai)
3. Sodium- carboxy methly cellulose "Na-CMC" supplied (Loba Chemie Pvt. Ltd., Mumbai)
4. Sodium phosphate monobasic and sodium phosphate dibasic (Acros organic Ltd., Mumbai)
5. Parabens (Loba Chemie Pvt. Ltd., Mumbai)

Method of preparation:

GSE mucoadhesive gel preparation:

\- Formula 1: 2% GSE mucoadhesive gel based on minimum inhibitory concentration (MIC) and minimum toxic concentration (MTC) and depending on the concentration of adhesive polymers that were added to the formula.

Weighed CB 934 was dissolved in 50 ml of phosphate buffer of pH 6.6 with a vigorous mixing until it dissolved completely. Then, GSE and preservatives were dissolved in about 25 ml of phosphate buffer of pH 6.6. After that, the GSE solution was slowly added into the solution of CB 934 with a continuous stirring that was achieved by magnetic stirring at a speed of 100 rpm until a homogenous mixture was obtained. The gelling agent (Na-CMC) was added slowly under a continuous magnetic stirring. Then, the volume was increased up to 100 ml with the addition of phosphate buffer. Finally, the prepared gel was kept for 24 hours at room temperature (25°C) for a complete polymer dissolution.

\- Formula 2: controlled gel without GSE. A controlled mucoadhesive gel was used in the clinical study to be compared with GSE gel. This control gel contained all above mentioned substances except for the GSE.

Microbial limit test:

One gram of the gel was suspended in 2.9 ml of phosphate buffer at pH 7.2. Different sterile media (Bismuth Sulfite Medium, Mannitol salt agar medium, Muller Hinton agar medium, cetrimide agar medium and sabaroud agar medium) were inoculated with the gel, then, incubated for 24 hours. After that, the media were examined to ensure no growth of bacterial genera.

Subjects:

A random sample of 24 patients were screened and examined. Five patients with mean age 43.5 ±7.9 years were found to comply with the study inclusion criteria

Baseline measurements and application of gels A total of 86 Sites of pocket depth (PD) of 5 mm and above were identified. Sites were divided randomly by split mouth technique into two groups: Test group (GSE group) who will receive GSE mucoadhesive gel (N=48) and Control group who will receive the control gel (N=38). The two prepared formulas were placed in identical containers providing that neither the patient, nor the clinician were aware of which was applied on which quadrant of the mouth "i.e. double blinded study".

In the first visit, an informed written consent was obtained from all patients. scaling and root planing (SRP) were performed by the same calibrated examiner using an ultrasonic scaler (miniPiezon, EMS, Switzerland) and Gracey curettes (Hu-Friedy Mfg, USA). Seven days after, the patients were recalled for clinical examination and baseline measurement (T0) were taken for Plaque index (PI), Gingival index (GI), Pocket depth (PD), and bleeding on probing (BOP) by a single calibrated examiner. PD was measured using a manual probe (UNC 15). PI and GI were assessed according to Silness and Loe (1964). BOP was assessed within 30 seconds after probing. In the same visit, the examiner applied the two prepared formulas into two opposite quadrants using a disposable syringe with a 23-gauge needle. Patients were given oral hygiene instructions and were instructed not to drink or eat for a minimum of 3 hours, not to brush the area for 24 hours and not to use mouth wash during the course of treatment.

The patients were recalled again after 3, 6, and 9 days to reapply the two formulas in the examined sites by the same examiner.

Revaluation The first re-evaluation visit (T1) was after 28 days from the baseline measurements (T0). During this visit, the calibrated clinician measured and recorded PI, GI, PD, BOP for all examined sites.

The second re-evaluation visit (T2) was after 6 months from the baseline measurements (T0) and the same measurements were retaken for all sites.

Statistical Package for the Social Sciences (SPSS) v20 package (IBM Corp) was used for statistical analysis. Significance of the change in PI, GI, and PD within each group were determined using paired t-test while the significance of difference in the change between the two groups was determined using the independent t-test. The difference was considered statistically significant at p \< 0.05.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Periodontitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GSE mucoadhesive gel

2%GSE mucoadhesive gel administered in the periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0

Group Type EXPERIMENTAL

2% GSE mucoadhesive gel

Intervention Type DIETARY_SUPPLEMENT

2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0

Control mucoadhesive gel

GSE free mucoadhesive gel administered in the periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0

Group Type PLACEBO_COMPARATOR

GSE free mucoadhesive gel

Intervention Type OTHER

GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

2% GSE mucoadhesive gel

2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0

Intervention Type DIETARY_SUPPLEMENT

GSE free mucoadhesive gel

GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* being medically fit
* non-smokers
* has clinical diagnosis of chronic periodontitis with pockets depth of 5mm or greater along with evident radiographic bone Loss, and acceptance to provide an informed consent

Exclusion Criteria

* pregnant patients
* breastfeeding mothers
* patients who are taking dietary supplements
* patients known to have grape's allergy
* patients with hypertension or bleeding disorders
* patients who have been under systemic or topical antibiotic treatments in the last 3 months
* smokers, and patients who are taking any medications that may interact with GSE
Minimum Eligible Age

35 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Riyadh Colleges of Dentistry and Pharmacy

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohammad Ramadan Rayyan

Assistant professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohammad Rayyan, MDS

Role: PRINCIPAL_INVESTIGATOR

Assistant professor

Tammam S Terkawi, MSc

Role: PRINCIPAL_INVESTIGATOR

Lecturer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Riyadh colleges of dentistry and pharmacy

Riyadh, Riyadh Region, Saudi Arabia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Saudi Arabia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FUGRP/2014/182

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bacteremia in Periodontal Patients
NCT02215473 COMPLETED PHASE4
Microbiome Alterations With Xylitol (MAX) in Pregnancy
NCT06329596 ACTIVE_NOT_RECRUITING PHASE1/PHASE2